UPDATE : Monday, July 13, 2020
상단여백
‘Remdesivir cut death risk by 62% in severely ill Covid-19 patients’ by Kim Yun-mi 2020-07-13 14:44
Multinational drugmakers seek to form new trade union by Kim Yun-mi 2020-07-13 11:44
Will Biogen win FDA nod for Alzheimer’s drug aducanumab? by Kim Yun-mi 2020-07-09 16:06
Regulator to reclassify dermatological cream Lidomex as prescription drug by Kim Yun-mi 2020-07-08 11:24
‘Study results on MSD’s Keytruda very disappointing’ by Kim Yun-mi 2020-07-07 16:43
라인
Experts showed mixed preferences between 2 diabetes treatments by Kim Yun-mi 2020-07-06 14:20
MSD Korea reshuffles personnel before spinoff of Organon by Kim Yun-mi 2020-07-02 13:44
[Special] HIV patients pushed aside amid Covid-19 crisis by Kim Yun-mi 2020-07-01 16:18
Hanmi, Novartis in patent dispute over diabetes drug by Kim Yun-mi 2020-06-25 13:59
Labor-management dispute runs deep at MSD Korea by Kim Yun-mi 2020-06-23 12:06
라인
RIGHT Fund adds ₩18 billion to support for infectious disease research by Kim Yun-mi 2020-06-22 17:22
‘Pfizer’s Vyndaqel, Vyndamax do not deserve rare disease pricing’ by Kim Yun-mi 2020-06-22 17:19
New diabetes drug Steglatro fails to prove cardiovascular benefit by Kim Yun-mi 2020-06-19 14:55
AZ’s Imfinzi wins extra indication for small-cell lung cancer by Kim Yun-mi 2020-06-18 15:55
Lilly beats Pfizer in treating early breast cancer by Kim Yun-mi 2020-06-18 14:44
라인
‘Tecentriq, major turning point for triple-negative breast cancer treatment’ by Kim Yun-mi 2020-06-18 14:43
IOF aims to reduce osteoporosis-related fractures by 25% by 2025 by Kim Yun-mi 2020-06-17 14:28
Regulator to discuss re-evaluation of choline alfoscerate by Kim Yun-mi 2020-06-17 12:36
‘Celltrion has no reason to save Takeda Korea workers’ jobs’ by Kim Yun-mi 2020-06-16 11:44
Jardiance family of diabetes drugs sells ₩10 billion in Q1 by Kim Yun-mi 2020-06-15 17:39
여백
여백
여백
Back to Top